The pharmacokinetics of saquinavir: A Markov chain Monte Carlo population analysis

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 26, Issue 1, 1998, Pages 47-74

  Lunn, David J ^a   Aarons, Leon ^b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Gibbs sampler; Hierarchical models; Markov chain Monte Carlo; Population analysis; Saquinavir

Indexed keywords

ANTIRETROVIRUS AGENT; GAG PROTEIN; PROTEINASE INHIBITOR; SAQUINAVIR;

ADULT; ALGORITHM; ANTIVIRAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BAYES THEOREM; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DISPOSITION; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; POPULATION DYNAMICS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SYSTEM ANALYSIS;

ADOLESCENT; ADULT; ALGORITHMS; ANTI-HIV AGENTS; AREA UNDER CURVE; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; POPULATION; SAQUINAVIR;

EID: 0031660564     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. S. L. Beal and L. B. Sheiner. NONMEM User's Guide, parts I-VII, NONMEM Project Group, San Francisco, 1992.
2. PPHARM User's Manual. SIMED Scientific Software Development, Centre D'Etudes et de Recherches en Statistiques et Informatique Medicales, Paris, France, 1994.
3. P. J. Green. MCMC in image analysis. In W. R. Gilks, S. Richardson, and D. J. Spiegelhalter (eds.), Markov Chain Monte Carlo in Practice, Chapman and Hall, London, 1996, pp. 381-399.
4. S. Geman and D. Geman. Stochastic relaxation, Gibbs distributions and the Bayesian restoration of images. IEEE Trans. Pattn. Anal. Mach. Intell. 6:721-741 (1984).
5. C. Berzuini. Medical monitoring. In W. R. Gilks, S. Richardson, and D. J. Spiegelhalter (eds.), Markov Chain Monte Carlo in Practice, Chapman and Hall, London, 1996, pp. 321-337.
6. A. Mollié. Bayesian mapping of disease. In W. R. Gilks, S. Richardson, and D. J. Spiegelhalter (eds.), Markov Chain Monte Carlo in Practice, Chapman and Hall, London, 1996, pp. 359-379.
7. J. C. Wakefield. An expected loss approach to the design of dosage regimens via sampling-based methods. The Statistician 43:13-29 (1994).
8. N. G. Best, K. K. C. Tan, W. R. Gilks and D. J. Spiegelhalter. Estimation of population pharmacokinetics using the Gibbs sampler. J. Pharmokin. Biopharm. 23:407-435 (1995).
9. D. J. Lunn and L. J. Aarons. Markov chain Monte Carlo techniques for studying interoccasion and intersubject variability: application to pharmacokinetic data. Appl. Statist. 46:73-91 (1997).
10. R. Yarchoan, H. Mitsuya and S. Broder. AIDS therapies. Sci. Am. 259:88-97 (1988).
11. P. E. O. Williams, M. J. Madigan, A. M. Mitchell, G. J. Muirhead and T. Shaw. A single dose, randomised, crossover study of the absolute and relative bioavailability of Ro 31-8959 in healthy volunteers. (Protocol P-8016.) Roche Res. Rep. W-141786, 1992. (Roche data on file).
12. SIPHAR User's Manual. SIMED Scientific Software Development, Centre D'Etudes et de Recherches en Statistiques et Informatique Medicales, Paris, France, 1988.
13. T. M. Shaw, G. J. Muirhead, M. J. Madigan, A. M. Mitchell, F. Schoutsen, A. Houston and L. Vann. A single and multiple dose, placebo-controlled, tolerability and pharmacokinetic study of four dosages of Ro 31-8959 in healthy volunteers. (Protocol P-5176.) Roche Res. Rep. W-144864, 1992. (Roche data on file).
14. G. Roncari, F. Stewart, T. Shaw, J. Bock, M. Bryant, S. Harris and A. N. Brown. An open, randomised, cross-over study of the pharmacokinetic interaction of Ro 31-8959 and ketoconazole in healthy volunteers. (Protocol WK-14435.) Roche Res. Rep. B-162077, 1994. (Roche data on file).
15. A. E. Gelfand and A. F. M. Smith. Sampling-based approaches to calculating marginal densities. J. Am. Statist. Assoc. 85:398-409 (1990).
16. J. C. Wakefield, A. F. M. Smith, A. Racine-Poon and A. E. Gelfand. Bayesian analysis of linear and non-linear population models using the Gibbs sampler. Appl. Statist. 43:201-221 (1994).
17. C. N. Morris and S. L. Normand. Hierarchical models for combining information and for meta-analyses. In J. M. Bernardo, J. O. Berger, A. P. Dawid, and A. F. M. Smith (eds.), Bayesian Statistics 4, Oxford University Press, Oxford, U.K., 1992, pp. 321-344.
18. M. E. DeGroot. Optimal Statistical Decisions, McGraw-Hill, New York, 1970.
19. A. F. M. Smith and G. O. Roberts. Bayesian computation via the Gibbs sampler and related Markov chain Monte Carlo. J. R. Statist. Soc. B, 55:3-23 (1993).
20. W. R. Gilks. Full conditional distributions. In W. R. Gilks, S. Richardson, and D. J. Spiegelhalter (eds.), Markov Chain Monte Carlo in Practice. Chapman and Hall, London, 1996, pp. 75-88.
21. N. Metropolis, A. W. Rosenbluth, M. N. Rosenbluth, A. H. Teller and E. Teller. Equations of state calculations by fast computing machines. J. Chem. Phys. 21:1087-1091 (1953).
22. W. K. Hastings. Monte Carlo sampling-based methods using Markov chains and their applications. Biometrika 57:97-109 (1970).
23. L. Tierney. Markov chains for exploring posterior distributions. Ann. Statist. 22:1701-1762 (1994).
24. M. K. Cowles and B. P. Carlin. Markov chain Monte Carlo convergence diagnostics: a comparative review. J. Am. Statist. Assoc. 91:883-904 (1996).
25. A. E. Raftery and S. Lewis. How many iterations in the Gibbs sampler? In J. M. Bernardo, J. O. Berger, A. P. Dawid, and A. F. M. Smith (eds.), Bayesian Statistics 4. Oxford University Press, Oxford, U.K., 1992, pp. 763-773.
26. J. Wakefield and A. Racine-Poon. An application of Bayesian population pharmacokinetic/ pharmacodynamic models to dose recommendation. Statist. Med. 14:971-986 (1995).